BioPhenyx is the first company in the world that quantitatively determines how genetic sequence variants (“what is coded?”) impact cell phenotypes (“what happens?”). BioPhenyx exploits its proprietary, ground-breaking CRISPR-Select technology to determine effects of mutations and drugs in cell cultures, as reported in Nature Genetics. CRISPR-Select provides fast and – importantly – conclusive results by introducing and quantitatively tracking a mutation of interest and neutral, internal control mutations. BioPhenyx is currently serving customers ranging from big pharma to small-scale biotech enterprises to working with partners in the clinic.